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AbstrAct
Objectives The present study aimed to assess the 
relationship between inflammatory disorders with 
cardiometabolic diseases and mortality within a 
community-based population.
Methods The UK Biobank data were used to 
conduct two investigations: a cross-sectional study to 
estimate cardiometabolic risk and a prospective cohort 
study to estimate mortality risk. Binary regression 
analyses were used to model the association between 
coronary heart disease, stroke, type 2 diabetes, venous 
thromboembolism and peripheral artery disease 
diagnoses with seven inflammatory disorders (eg, 
rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), psoriasis, ankylosing spondylitis (AS), systemic 
vasculitis, Crohn’s disease and ulcerative colitis (UC)). 
Cox proportional hazards was used to estimate all-cause 
and cardiovascular-related mortality.
results About 4% (n=19, 082) of the study 
population (n=5 02 641) were diagnosed with a chronic 
inflammatory disorder. The most common inflammatory 
disorder was psoriasis (n=6286), and the least common 
was SLE (n=654). SLE showed the strongest association 
with multiple (relative risk (RR) 6.36, 95% CI 4.37 to 
9.25) risk of cardiometabolic diseases, followed by the 
RA (RR 1.70, 95% CI 1.59 to 1.83), UC (RR 1.69, 95% 
CI 1.51 to 1.89), AS (RR 1.28, 95% CI 1.09 to 1.52), 
vasculitis (RR 1.64, 95% CI 1.42–1.90) and psoriasis (RR 
1.25, 95% 1.16 to 1.35) disorders. The magnitude of the 
association was higher among participants prescribed 
non-steroidal anti-inflammatory drugs or corticosteroids 
drugs, with multiple cardiometabolic risk being greater 
within SLE (RR 12.35, 95% CI 7.18 to 21.24), followed 
by UC (RR 3.81, 95% CI 2.69 to 5.38), Crohn’s disease 
(RR 3.07, 95% CI 1.85 to 5.11), RA (RR 3.06, 95% 
CI 2.44 to 3.85), psoriasis (RR 2.36, 95% CI 1.88 to 
2.95), AS (RR 2.25, 95% CI 1.48 to 3.41) and vasculitis 
(RR 1.89, 95% CI 1.28 to 2.79). Similar pattern was 
observed with respect to the cumulative cardiometabolic 
risk.
conclusion Inflammatory disorders are associated with 
heightened risk of cardiometabolic events, which may 
vary by anti-inflammatory therapy and duration. All-cause 
mortality was also higher among specific inflammatory 
disorders compared with the absence of inflammatory 
disorders.
IntrOductIOn
An accumulating body of evidence documents an 
important role of inflammation in cardiovascular 
disease (CVD) onset and prognosis. Patients diag-
nosed with chronic inflammatory disorders (eg, 
rheumatoid arthritis (RA), systemic lupus erythe-
matosus (SLE), psoriasis) have an increased risk 
of coronary heart disease (CHD), stroke, type 2 
diabetes (T2DM), peripheral artery disease (PAD), 
venous thromboembolism (VTE) and CVD-re-
lated mortality.1–6 Emerging evidence suggests 
similar associations for ankylosing spondylitis 
(AS), Crohn’s disease and ulcerative colitis (UC), 
although this evidence is less consistent.7 8 In a 
prospective primary care cohort, we have docu-
mented an increased risk of CVD events associ-
ated with diverse chronic inflammatory disorders.1 
Socioeconomic disadvantage (eg, unemployment) 
experienced by these patients may underlie dispari-
ties in incidence and prevalence of cardiometabolic 
disorders and are often major barriers to chronic 
disease prevention and management.9 Because such 
information is less available in patients’ medical 
records, we have decided to investigate whether our 
previous study findings from a primary-care context 
are transferable to a community-based population 
with a richer sociodemographic data. The aim of 
the present study was to strengthen the evidence of 
the original study, to clarify additional issues (eg, 
anti-inflammatory therapy) and extend its gener-
alisability to other disorders (eg, ankylosing spon-
dylitis) or outcome measures (eg, mortality, PAD, 
VTE). Given the evidence for increased risk of 
CVD associated with corticosteroids in the general 
population,10 we hypothesised that the association 
between inflammatory disorders with cardiomet-
abolic events will be greater among participants 
treated with corticosteroids or non-steroidal 
anti-inflammatory drugs (NSAIDs).
MethOds
data
The data for the present study come from the UK 
Biobank, a large population-based prospective 
study developed to facilitate detailed investiga-
tions about the non-genetic and genetic determi-
nants of diseases in middle and old age. The UK 
Biobank collects detailed phenotype and genotype 
data from over half a million participants aged 40 
to 69 (502 641), including lifestyle, demographics, 
clinical diagnoses, treatment and genotype informa-
tion.11 There are also plans to incorporate previous 
medical diagnostic codes, imaging and biomarkers 
data in the near future. The present study used 
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the baseline data to investigate the cross-sectional association 
between inflammatory disorders with cardiometabolic risk. In 
addition, prospective data on mortality was used to investigate 
the longitudinal association between inflammatory disorders 
with mortality. For both cross-sectional and prospective inves-
tigations, participants reporting a previous diagnosis of RA, 
SLE, psoriasis, AS, systemic vasculitis, Crohn’s disease and UC 
disorders represented the exposed group, while those reporting 
none of these disorders constitute the comparison group. A 
more detailed description of the UK Biobank data is provided 
elsewhere.11
The UK Biobank has generic ethics approval from the 
National Health Service National Research Ethics Service (Ref: 
11.NW/0382) and all participants provided written informed 
consent.
Outcomes
Main outcome variables
Self-report of a clinician diagnosis of CHD (ie, myocardial infarc-
tion, angina), stroke, T2DM, PAD and VTE events were used to 
develop the primary outcome measures for the cross-sectional 
investigation. Traditionally, T2DM is considered an independent 
risk factor for CVD, and adjusted accordingly. Reflective of the 
common origins hypothesis,12 T2DM and CVDs are gradually 
operationalised as a multifaceted construct—the cardiometa-
bolic disorder.13 14 This framework was adopted in our recent 
investigation1 that documented chronic inflammation as a risk 
factor for both T2DM and CVD disorders implying a possible 
role of the inflammatory process in the origin of both CVD and 
T2DM disorders. Cardiometabolic events are defined using the 
International Classification of Diseases, edition 10 (ICD-10). 
To reflect the possibility that inflammatory disorders are asso-
ciated with diverse cardiometabolic disorders two composite 
binary measures were developed. A cumulative cardiometa-
bolic measure that classified patients into those with at least one 
cardiometabolic event (1) versus those without an event (0); and 
a multiple cardiometabolic measure that grouped participants 
into those with two or more cardiometabolic events (1) versus 
those with one or no cardiometabolic event (0).
Secondary outcome variables
Official data from the National Health Service’s Centre Registry 
were used to develop two binary (yes/no) secondary outcomes 
measures: all-cause mortality and CVD-related mortality.
Exposures
The study exposures were represented by seven chronic inflam-
matory disorders, namely RA, psoriasis, Crohn’s disease, UC, 
SLE, systemic vasculitis and AS. These measures were based 
on participants self-report of a clinician diagnosis and were 
developed into separate binary variables (yes/no). To test the 
hypothesis that cardiometabolic events and mortality rates may 
vary with anti-inflammatory therapy and disorder duration, 
two additional variables were developed for each inflamma-
tory disorder. A therapy variable that used anti-inflammatory 
prescribing data to classify participants into: no anti-inflam-
matory therapy, NSAIDs or corticosteroids only therapy, and 
disease-modifying antirheumatic drugs (DMARDs). An inflam-
matory  disorder duration variable based on the number of 
years from inflammatory disorder diagnosis to the year of the 
UK Biobank assessment. This variable grouped participants into 
tertiles of inflammatory disorder duration.
Covariates
Because of the cross-sectional nature of the data at baseline, 
the study covariates included sociodemographic characteristics, 
specifically age (continuous measure), gender (female vs male), 
deprivation, education and ethnicity. Deprivation was based on 
Townsend deprivation indices derived from aggregated data on 
car ownership, household overcrowding, owner occupation and 
unemployment (higher scores represent higher degree of depri-
vation). For the present study, participants were grouped into 
quintiles of deprivation. Education (options included degree, 
Advanced(A) levels/Advanced Subsidiary(AS) levels, O levels/
General Certificate of Secondary Education (GCSE), Certificate 
of Secondary Education (CSEs), National Vocational Qualifica-
tion (NVQ)/Higher National Diploma (HND)/Higher National 
Certificate (HNC) or none) was included as a binary variable 
comparing participants with a degree or professional quali-
fication with those with other qualifications.15 Self-reported 
ethnicity classified participants into white, Asian (eg, India, 
Pakistan or Bangladesh), Chinese, black, or mixed/other. Life-
style factors (eg, smoking, physical activity, diet, obesity) are 
important risk factors for CVD, however, because these were 
measured at the date of assessment adjusting for them in the 
analysis may have introduced bias (their value is likely to have 
changed over time). As educational level is related to lifestyle 
factors, we adjusted for this factor in the analyses. Two addi-
tional binary (yes/no) covariates were included in the sensitivity 
analyses: self-reported antihypertensive therapy and lipid-low-
ering therapy. Data on the prevalence of atherogenic risk factors 
(eg, smoking, body mass index, hypertension, dyslipidaemia) are 
provided in the online supplementary table S1.
statistical methods
Cross-sectional study
Descriptive analyses were used to explore differences in demo-
graphics characteristics between participants with and without 
a diagnosis of chronic inflammatory disorder. Multivariable 
binomial regression analysis was used to estimate the cross-sec-
tional association between each inflammatory disorder with each 
primary cardiometabolic outcome measure. The same modelling 
strategy was used to estimate the association between anti-in-
flammatory therapy and length of exposure. Binomial regression 
modelling was preferred to logistic regression as it allows an 
estimation of the relative risk of study outcomes, the preferred 
estimate when the outcomes’ incidence is common.16 The anal-
yses adjusted for age, sex, deprivation, ethnicity and educational 
level. Sensitivity analyses adjusting (in addition to study covari-
ates) for antihypertensive and lipid-lowering drugs were also 
performed.
Prospective study
Cox proportional hazards regression was used to estimate differ-
ences in all-cause and CVD-related mortality rates between 
participants with and without a diagnosis of chronic inflamma-
tory disorder. These analyses adjusted for age, sex, deprivation, 
ethnicity and educational level. Participants entered the study 
at the time of baseline assessment and exited at the time of 
death or study end. The proportionality assumption was tested 
using Schoenfeld residuals and was found not to be violated. 
Sensitivity analyses excluding participants with cardiometabolic 
disorders at baseline were also performed (data available from 
the authors).
Within both cross-sectional and prospective studies, 
random-effects meta-analysis was used to obtain a pooled 
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estimate of the relative risk of primary and secondary outcomes 
within specific inflammatory disorders. Because adjustment 
for multiple comparisons could increase the risk of type II 
errors,17 we have interpreted statistical significance within the 
context of the magnitude of association and previous research 
findings.17 Because less than 0.01% of the data were missing, 
complete case analyses were performed. All analyses were 
conducted using STATA V.14, using p <0.5 as the threshold for 
statistical significance.
results
A total of 19 082 (4%) participants with a prior diagnosis of 
chronic inflammatory disorder have been identified. The most 
common inflammatory disorders were psoriasis (31%) and RA 
(28%), followed by Crohn’s disease (13%), UC (7%) ankylosing 
spondylitis (7%), vasculitis (7%) and SLE (3%) (table 1). The 
mean age at inflammatory disorder diagnosis ranged from 33 
years (psoriasis) to 57 years (systemic vasculitis). A larger propor-
tion of participants diagnosed with inflammatory disorders were 
in the most deprived quintile relative to the comparison group. 
With respect to ethnicity, participants of Asian origins reported a 
threefold increase in the rates of SLE relative to the comparison 
group.
cross-sectional results
Table 2 illustrates the distribution of study primary outcome 
measures within specific inflammatory disorders and the compar-
ison group. The most common combination of specific outcomes 
and multiple outcome is also reported. Multiple cardiometabolic 
diseases were more common among SLE (4%) and vasculitis 
(4%) disorders, and less common among participants reporting 
Crohn’s disease (2%) or psoriasis (2%) disorders. Participants 
diagnosed with SLE presented the highest rates of cardiomet-
abolic events, with the exception of T2DM which was more 
common among participants reporting RA (6%), vasculitis (6%) 
or psoriasis (6%) disorders. The most common combination of 
cardiometabolic disorders were CHD with T2DM, CHD with 
VTE and CHD with stroke.
Binary regression results revealed increased risk of 
cardiometabolic diseases (online supplementary table S2) 
within most inflammatory disorders. The strongest association 
was revealed with respect to SLE and PAD disorders (rela-
tive risk (RR) 17.24, 95% CI 11.36 to 26.19). Participants 
diagnosed with RA were associated with increased risk of all 
cardiometabolic outcome measures. The association for other 
disorders tended to be restricted to specific cardiometabolic 
disorders.
table 1 Participants characteristics at baseline assessment. Figures are numbers and percentages unless otherwise specified
rA, n=5764 Psoriasis, n=6286 As, n=1400 Vasculitis, n=1475 sle, n=654 uc, n=2659 cd, n=1494 unexposed, n=483 559
Age—mean (SD) 46 (14) 33 (17) 37 (13) 57 (11) 42 (12) 39 (13) 36 (14) 57 (8)
Gender —Female 4014 (70) 2991 (48) 528 (38) 986 (67) 582 (89) 1427 (54) 861 (58) 261 549 (54)
Ethnicity
  White 5431 (94) 6070 (96) 1352 (97) 1435 (98) 561 (86) 2542 (96) 1451 (98) 453 485 (94)
  Mixed 135 (2) 98 (2) 13 (1) 9 (1) 23 (4) 57 (2) 21 (1) 9512 (2)
  Asian 73 (1) 16 (0) 4 (0) 8 (0) 42 (6) 16 (1) 9 (1) 7887 (2)
  Black 38(1) 31(1) 8 (1) 6 (0) 10 (2) 13 (0) 3 (0) 2850 (1)
  Other 54 (1) 41 (1) 13 (1) 10 (1) 13 (2) 23(1) 4 (0) 6019 (1)
Deprivation quintile
  Least deprived 1015 (18) 1181 (19) 268 (19) 321 (22) 115 (18) 539 (20) 274 (18) 96 898 (20)
  Second 1011 (18) 1185 (19) 277 (20) 287 (20) 110 (17) 552 (21) 289 (18) 96 292 (20)
  Third 1107 (19) 1229 (19) 262 (19) 333 (23) 120 (18) 550 (21) 286 (19) 96 418 (20)
  Fourth 1176 (20) 1266 (20) 283 (20) 296 (20) 128 (20) 551 (21) 314 (21) 96 240 (20)
  Most deprived 1445 (25) 1420 (23) 309 (22) 235 (16) 180 (28) 464 (17) 327 (22) 95 935 (20)
Qualifications
  Degree level 434 (8) 614 (10) 139 (10) 126 (9) 58 (9) 248 (9) 134 (9) 53 777 (11)
AS, ankylosing spondylitis; CD, Crohn’s disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis.
table 2 Prevalence of individual and most common combination of cardiometabolic outcomes by study inflammatory disorders
chd+t2dM chd+stroke chd+Vte chd+PAd Vte t2dM chd stroke PAd Multiple
RA 66 (1) 36 (1) 48 (1) 8 (0) 269 (5) 345 (6) 484 (8) 162 (3) 52 (1) 187(3)
Psoriasis 71 (1) 17(0) 16 (0) 6 (0) 176 (3) 367 (6) 379 (6) 103 (2) 29 (1) 127 (2)
AS 18 (1) 11 (1) 8 (1) 2 (0) 45 (3) 75 (5) 100 (7) 38 (3) 8 (1) 40 (3)
Vasculitis 16 (1) 11 (1) 11 (1) 1 (0) 100 (7) 83 (6) 108 (7) 48 (3) 15 (1) 54 (4)
SLE 2 (0) 9 (1) 11 (2) 4 (1) 83 (13) 27 (4) 52 (8) 39 (6) 25 (4) 33 (4)
UC 26 (1) 7 (0) 21 (1) 2 (0) 148 (6) 142 (5) 172 (6) 49 (2) 15 (1) 70 (3)
CD 8 (1) 7 (1) 6 (0) 0 (0) 69 (5) 53 (4) 62 (4) 23 (2) 12 (1) 25 (2)
Non-exposed 3134 (1) 1325 (0) 1252 (0) 197 (0) 12 131 (3) 19 949 (4) 21 857(5) 7425(2) 1350 (0) 6901 (1)
The figures represent the number and percentage (brackets) of participants diagnosed with cardiometabolic events out of the total within each condition or non-exposed group.
AS, ankylosing spondylitis; CD, Crohn’s disease; CHD, coronary heart disease; Multiple, two or more outcome measures (participants from previous columns are also included 
in this column); PAD, peripheral artery disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T2DM,  type 2 diabetes mellitus; UC, ulcerative colitis; VTE, venous 
thromboembolism.
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Figure 1 illustrates that participants diagnosed with SLE 
presented a sixfold adjusted increased risk of multiple (RR 6.36, 
95% CI 4.37 to 9.25) cardiometabolic events. The RR for pooled 
estimate for multiple and cumulative cardiometabolic events was 
1.70 (95% CI 1.32 to 2.08). A similar pattern was observed with 
regards to the cumulative cardiometabolic outcome where the 
pooled effect size was 1.77 (95% CI 1.45 to 2.10) (online supple-
mentary figure S1).
Figure 2 illustrates that the highest adjusted RR of multiple 
cardiometabolic events was observed among participants 
reporting NSAIDs or corticosteroids only therapy. For instance, 
patients diagnosed with SLE presented a 12-fold adjusted 
increased risk of multiple cardiometabolic events (RR 12.35, 
95% CI 7.13 to 21.24) compared with those without an 
inflammatory disorder. No statistically significant associa-
tion was observed among participants without self-reported 
Figure 1 Forest plot displaying random effects meta-analysis of the association between chronic inflammatory disorders with multiple 
cardiometabolic outcomes. The lines around the dot represent the 95% CI for the effect size. The line drawn perpendicular to the x axis represents the 
null hypothesis (RR=1). RR, relative risk.
Figure 2 Forest plot displaying random effects meta-analysis for multiple cardiometabolic outcome among participants diagnosed with specific 
inflammatory disorders who reported no drug therapy, with NSAIDs or corticosteroids only therapy, or with DMARDs therapy compared with those 
free of inflammatory disorders. RR, relative risk. The line drawn perpendicular to the x axis represents the null hypothesis (RR=1). DMARDs, disease-
modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs.
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anti-inflammatory drugs therapy (with the exception of SLE). 
Similar findings were revealed with regards to the cumulative 
cardiometabolic outcome events (online supplementary figure 
S2). Concerning the duration of inflammatory disorders, an 
increasing dose–response relationship was observed among 
participants diagnosed with SLE and RA disorders, while the 
opposite trend was observed among participants diagnosed with 
psoriasis, AS and UC disorders (online supplementary figures S3 
and S4). The findings for individual cardiometabolic outcome 
are presented in online supplementary figures S3 and S4).
Prospective study
Figure 3 illustrates that participants diagnosed with SLE 
presented with the highest adjusted HR of all-cause mortality 
(HR 2.06, 95% CI 1.37 to 3.10) compared with the comparison 
group. The pooled estimates for all-cause were 1.52 (95% CI 
1.28 to 1.76). Similar patterns were observed with regards to 
CVD-related mortality outcome analysis (online  supplementary 
figure S5).
sensitivity analyses
Sensitivity analyses that also adjusted for antihypertensive and 
lipid lowering drugs validated the main study findings with 
regards to cardiometabolic outcomes (online  supplemen-
tary figure S5). Also, analyses that excluded participants with 
cardiometabolic events at baseline validated the study findings 
about mortality outcomes (data not shown).
dIscussIOn
Primary outcome measures: cross-sectional study findings
The aim of the present study was to replicate in a communi-
ty-setting the relationship between specific chronic inflamma-
tory disorders with cardiometabolic outcomes documented in a 
primary care context, using a similar methodological approach. 
Adjusting for critical socioeconomic inequalities, the present 
study findings endorsed the increased risk of cardiometabolic 
events (eg, CHD, stroke, T2DM) within specific chronic inflam-
matory disorders and extended these associations to other 
disorders (eg, AS) and outcome measures (eg, PAD, VTE). A 
notable finding was that participants diagnosed with patho-
logically diverse inflammatory disorders were at greater risk of 
both multiple and cumulative cardiometabolic events compared 
with their counterparts without inflammatory disorders. The 
large effect size observed for PAD outcome (specifically within 
the SLE disorder) relative to other outcome measures (ie, CHD, 
stroke) indicates a possible strong association, however, the wide 
confidence intervals questions the precision of the estimates. 
This association would benefit, thus, from confirmation with 
larger prospective studies.
Overall, these associations were stronger among participants 
who were prescribed NSAIDs or corticosteroids, potentially 
reflecting the increased CVD risk associated with some of these 
drugs. Participants who were prescribed DMARDs also presented 
greater rates of cardiometabolic events, but the magnitude of the 
association was lower. Confounding by indication may explain 
the findings for DMARDs, given their prescribing indication for 
patients with more severe underlying inflammation. This sugges-
tion is supported by the evidence of no increased cardiometa-
bolic risk among participants who did not report anti-inflam-
matory therapies. Patients prescribed DMARDs are likely also 
to be prescribed NSAIDs or corticosteroids to alleviate disor-
der-related pain. Thus, the association may be confounded by 
the increased cardiometabolic risk confer by NSAIDs or corti-
costeroid drugs.18 Certain DMARDs (eg, leflunomide and ciclo-
sporin) have also been linked with increased risk of hyperten-
sion,19 which may also account for the observed association.
A dose-response association was observed with respect to 
the duration of inflammatory disorder. Specifically, the risk of 
cardiometabolic events increased with the duration of RA, SLE, 
and systemic vasculitis (cumulative outcome) disorders. A reverse 
trend was apparent, however, within Crohn’s disease, UC and 
psoriasis (cumulative events) disorders. This reverse trend may 
be due to an effective disorder management that may obscure a 
potential association between disorder duration with cardiomet-
abolic risk. There are also suggestions that reduced CVD risk 
with longer Crohn’s disease duration may be due to progression 
from an inflammatory to a fibrostenotic disorder phenotype.20
The simultaneous investigation of cumulative and multiple 
cardiometabolic risk within pathologically diverse inflammatory 
disorders is rarely available.1 21 Using a primary-care popula-
tion, we have recently1 identified an increased risk of multiple 
CVD events within specific inflammatory disorders. The present 
study documented similar patterns within a community-based 
population and extended these findings to multiple cardiomet-
abolic outcomes and additional disorders (eg, AS). Previous 
research associated methotrexate use with lower CVD risk.22 23 
The present study findings imply increased cardiometabolic risk 
among DMARDs treated participants in line with Ogdie et al 
Figure 3 Forest plot displaying random effects meta-analysis for all-cause mortality among participants diagnosed with specific inflammatory 
disorders compared with those free of inflammatory disorders. The line drawn perpendicular to the x axis represents the null hypothesis (HR=1).
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findings.21 The eclectic definition of DMARDs (eg, metho-
trexate, ciclosporin, leflunomide, azathioprine) in this study 
may mask the impact of specific DMARDs on cardiometabolic 
risk. The study findings are in line with prior studies24suggested 
a decline in CVD risk associated with increased duration of 
Crohn’s disease and UC, while the reverse trend was suggested 
among SLE.25
secondary outcome measures: prospective findings
With the exception of UC, participants diagnosed with inflam-
matory disorders presented higher rates of all-cause and CVD-re-
lated mortality events relative to inflammatory disorder-free 
participants. These findings are consistent with prior evidence 
based on smaller samples.4 26 27
strengths And lIMItAtIOns
The present study has several strengths including large sample 
size with detailed information on socioeconomic factors, objec-
tively assessed mortality data, type of chronic inflammatory 
disorders and cardiometabolic diseases. The study population 
is representative of the UK population, supporting the gener-
alisability of the findings. As with most observational studies 
there are several limitations that need discussing. Our analysis 
for cardiometabolic risk was rather cross-sectional limiting any 
robust inferences about the temporal association between inflam-
matory disorders and cardiometabolic risk. However, the direc-
tion of the association and effect sizes were similar to previous 
prospective studies.1 Cardiometabolic and inflammatory disor-
ders events were identified via self-reports of a clinician diag-
nosis, increasing the risk of ascertainment bias but unlikely to 
introduce a systematic error.28 Possible decreased specificity of 
self-reported diagnoses may have led to overestimation of the 
reported rates of CVD events, especially among patients with 
chronic inflammatory disorders. This is particularly true for 
immune mediated inflammatory disorders (eg, SLE and RA) 
where common conditions such as pericarditis, myocarditis 
and pleuritis can mimic CHD; cerebritis can mimic stroke; and 
peripheral neuropathy may mimic peripheral vascular disease 
(PVD). Recent evidence29 documented, however, high validity 
and agreement rates between self-reported cardiometabolic 
events with medical records among patients diagnosed with RA. 
The prevalence rates of inflammatory disorders in this study are 
also in line with evidence from clinical settings.21 27 Also, the 
study findings are consistent with earlier results based on a large 
prospective study1 with primary care patients using physicians 
recorded diagnoses. Future plans to link the UK Biobank data 
with participants’ medical care records will provide the oppor-
tunity to validate the reliability of clinical diagnoses recording 
in the UK Biobank data. The study population was mainly white 
European with other ethnic groups being under-represented, 
questioning the generalisability of the study findings to non-white 
European populations. The number of outcome events across 
the different combinations of inflammation disorders was rela-
tively low, which may account for the apparent lack of statistical 
significance in some conditions (eg, Crohn’s disease). Finally, 
despite the large sample size available for analysis, the smaller 
number of cardiometabolic events (eg, PAD) may have inflated 
the magnitude of the observed association within some inflam-
matory disorders (eg, SLE), although unlikely to alter the direc-
tion of association or statistical significance. The prospective 
nature of the UK Biobank study will ensure increased incidence 
of cardiometabolic events providing for more precise estimates 
in future studies.
cOnclusIOn
Compared with the general population, adults diagnosed with 
clinically diverse inflammatory disorders present heightened 
rates of multiple cardiometabolic diseases. This risk varied 
with anti-inflammatory therapy and time of duration of the 
disorder. For some inflammatory disorders, the increased risk 
was detectable early in the course of disorder, supporting the 
public health value of early screening and effective intervention 
strategy. Recent evidence from primary care data30 suggests that 
we are falling short of this suggestion. The findings of increased 
cardiometabolic risks associated with NSAIDs and/or corticoste-
roids drugs reinforce the need for a more cautionary approach to 
the prescription of these drugs. The magnitude of the association 
for SLE supports the development of clinical recommendations 
for early screening and regular monitoring of cardiometabolic 
risk in these patients, similar to RA and psoriasis subgroups. 
Also, the evidence that cardiometabolic risk varied with anti-in-
flammatory therapy, endorses future evaluations into the poten-
tial role of specific DMARDs (alone or in combination with 
vascular risk therapies (ie, statins)) into the onset and prognosis 
of cardiometabolic events within specific inflammatory disorder. 
The UK Biobank follow-up is currently being conducted via 
linkage with electronic medical records that will, in due course, 
allow more robust evaluations of the history and treatment of 
specific inflammatory disorders, and how these factors influ-
ence the development and progression of specific and multiple 
cardiometabolic diseases. In addition, the availability of geno-
type and imaging data will provide improved opportunities for 
risk stratification and predictive biomarkers for early cardiomet-
abolic risk identification.
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Key messages
What is already known on this subject?
Previously we have identified a 20% overall increment in the risk 
of multiple cardiometabolic disorders among patients diagnosed 
with chronic inflammatory disorders in primary care settings. The 
generalisability of this finding to community-based populations 
is, however, uncertain.
What might this study add?
In a large community-based population, a 70% overall increment 
in the risk of multiple cardiometabolic disorders associated 
with chronic inflammation was observed. The overall risk of 
multiple cardiometabolic events was almost three times (relative 
risk=2.72) greater among participants prescribed non-steroidal 
anti-inflammatory drugs compared with those without a chronic 
inflammation diagnosis. Also, a 52% overall increased risk of 
all-cause mortality was observed among participants diagnosed 
with chronic inflammation relative to those without a chronic 
inflammation.
how might this impact on clinical practice?
The study findings confirm that inflammatory disorders increase 
risk of multiple cardiovascular events, similar to the risk 
conferred by diabetes mellitus and chronic kidney disease. This 
evidence endorses the development of specific clinical guidelines 
to facilitate cardiovascular disease risk prevention across diverse 
inflammatory disorders.
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